European municipal public health services face growing administrative pressure. Community health staff, including nurses, physiotherapists, psychologists, and social care workers, spend a rising proportion of their working day on documentation burden rather than direct patient contact. Municipalities also face rising demand for structured population-level reporting, workforce shortages, and political pressure to modernise public services without disrupting the workflows that keep community programmes running. AI-assisted documentation tools have entered this environment as a potential response to these pressures. For public health administrators, the decision to evaluate or pilot such a tool sits at the intersection of procurement law, data protection regulation, emerging AI legislation, medical device rules, and clinical governance, each with its own requirements, timelines, and internal stakeholders. This article sets out what administrators need to understand before they begin.

What AI-assisted documentation tools do in a public health context

AI-assisted documentation tools, sometimes called AI medical assistants or ambient documentation tools, capture spoken clinical encounters and convert them into structured clinical notes. In practice, a community health worker conducts a patient visit as normal. The tool listens, transcribes, and generates a draft note that the clinician reviews and approves before it enters the medical record system.

In a municipal public health context, this differs meaningfully from how similar tools operate in GP surgeries or hospital wards. Community health programmes are typically population-level and non-acute: they include home nursing visits, mental health follow-ups, rehabilitation sessions, health visitor appointments, and chronic disease management in the community. Documentation requirements tend to be high in volume, repetitive in structure, and spread across a dispersed workforce, often working across multiple locations without consistent administrative support.

The practical value in this setting is time recovery. A six-week pilot in Farsund Municipality, Norway, involving twenty employees across three care teams, found that total daily documentation time fell from approximately three hours to ten to fifteen minutes. The tool was tested in live patient conversations across community health settings, making it one of the few published evaluations conducted specifically within a European municipal public health programme.

A separate large-scale observational study across Capio/Ramsay Santé facilities in Sweden, evaluating an AI medical assistant across 375,000 clinical notes, found consistent reductions in self-reported documentation time across multiple care levels. That study was preregistered and adhered to SQUIRE reporting guidelines, making it one of the more methodologically rigorous real-world evaluations available.

Being precise about what these tools do not do in a standard documentation context matters here. They do not diagnose, prescribe, or generate clinical recommendations. They transcribe and structure what a clinician says and does during an encounter. That distinction has direct regulatory consequences, addressed below.

The EU AI Act: which risk classification applies to public health documentation tools

The EU AI Act came into force in August 2024 and establishes a tiered risk classification system for AI systems deployed in the EU. Understanding where a documentation tool sits within that framework is essential for administrators, because the classification determines the obligations that apply, both to the vendor and to the deploying organisation.

The Act distinguishes between high-risk AI systems and those that present lower or minimal risk. High-risk systems in healthcare are defined primarily as those used for diagnosis, treatment decisions, or clinical decision support that directly influences patient care outcomes. An AI system that generates clinical recommendations, flags diagnoses, or supports prescribing decisions is likely to fall within the high-risk category and must meet conformity requirements before deployment.

A documentation tool that captures and structures clinical encounters without generating clinical recommendations occupies a different position. Its primary function is administrative: converting speech to structured text for clinician review. Administrators should confirm with vendors whether their tool has been assessed under the EU AI Act and what risk classification applies, and request EU AI Act conformity documentation. Where a vendor claims a lower-risk classification, administrators should ask for a written rationale and verify that the tool does not include any decision-support features that would shift its classification.

The Act also introduces transparency obligations. Where AI systems interact with individuals, including patients, those individuals must be informed. Even in a documentation-only context, this has implications for how municipalities communicate with patients about what technology is present during their appointments.

GDPR obligations that apply before, during, and after piloting

Health data is special category data under Article 9 of the General Data Protection Regulation (GDPR). Processing it requires not only a lawful basis under Article 6 but an additional condition under Article 9, most commonly explicit consent, or processing necessary for the provision of health or social care under Article 9(2)(h). Municipal public health bodies need to determine which basis applies to their specific programme and document that determination before any pilot begins.

The key GDPR obligations administrators should address at each stage of a pilot are:

• Before piloting: Conduct a Data Protection Impact Assessment (DPIA). Under Article 35 of GDPR, a DPIA is mandatory when processing is likely to result in high risk to individuals, and processing special category health data using new technology meets that threshold. The DPIA should identify the risks, assess the necessity and proportionality of the processing, and document the measures taken to mitigate risk.

• During piloting: Apply data minimisation principles. The tool should process only the data necessary for the documentation function. Administrators should confirm that audio recordings are not retained beyond the period needed for transcription, and that the vendor does not use patient data for model training without explicit authorisation.

• After piloting and into deployment: Maintain records of processing activities under Article 30, ensure data subject rights can be exercised (including access and erasure), and review the data processing agreement with the vendor to confirm it reflects actual processing practices.

The data processing agreement between the municipality and the vendor is a contractual requirement under Article 28 of GDPR. It must specify the subject matter, duration, nature, and purpose of the processing, the type of personal data and categories of data subjects, and the obligations and rights of the controller. Administrators should not proceed to pilot without a signed data processing agreement in place.

Data residency and sovereignty: what European municipalities must confirm

For most European public health bodies, processing health data outside the EU/EEA is not permissible under their national data protection frameworks, regardless of what GDPR technically permits through transfer mechanisms. Several EU Member States have national legislation that imposes stricter requirements than the GDPR baseline, and many municipal procurement policies require explicit confirmation of EU data residency.

Before piloting, administrators should obtain written confirmation from the vendor on the following:

• Where audio data is processed (the server location at the point of transcription)

• Where structured notes are stored, and for how long

• Whether any sub-processors are involved, and where those sub-processors are located

• Whether any data is transferred outside the EU/EEA at any stage of the processing pipeline, including for model training or quality assurance

The European Health Data Space (EHDS), which entered into force in 2025, introduces additional infrastructure for cross-border health data use across the EU. Administrators should monitor how the EHDS interacts with national data residency requirements as its implementation progresses, particularly for municipalities operating cross-border health programmes.

Vendors based in or using infrastructure in the United States, United Kingdom, or other non-EEA countries should specify the legal transfer mechanism in use (for example, Standard Contractual Clauses) and confirm that no health data is processed on servers outside the EEA as part of normal operations.

Medical Device Regulation: when does it apply to documentation tools

The EU Medical Device Regulation (MDR) applies to software intended for a medical purpose, including diagnosis, prevention, monitoring, prediction, prognosis, treatment, or alleviation of disease. Whether an AI documentation tool falls within the MDR depends on what the software actually does, not what it is marketed as.

A tool whose sole function is to transcribe and structure clinical encounters, without generating any output that influences clinical decisions, is generally not considered a medical device under the MDR. However, if a tool includes features such as flagging clinical abnormalities, suggesting diagnoses, or prompting treatment considerations, those features may bring it within scope.

Administrators should:

• Ask vendors to provide a written MDR classification rationale

• Verify whether the tool holds a CE mark as a medical device, and if so, under which classification

• Confirm that any CE marking applies to the version of the tool being piloted, not a prior version

• Check whether the vendor has a Quality Management System certified to ISO 13485, which is required for medical device manufacturers

The medRxiv study evaluating the Tandem AI medical assistant across Swedish healthcare facilities is notable in that the tool evaluated was CE-marked, a data point relevant to administrators assessing what vendor certification looks like in practice for this category of tool.

Public procurement rules and how they shape the evaluation process

AI documentation tools procured by European municipal public health bodies are subject to the EU public procurement framework under Directive 2014/24/EU. The directive applies above defined financial thresholds. For public bodies at sub-central level, the current threshold for services contracts is €215,000 (net of VAT), though this figure is revised every two years by the European Commission and should be verified against the most recent Commission Delegated Regulation to confirm it remains current. Contracts above this threshold require a formal tender procedure published in the Official Journal of the EU.

Below threshold, municipalities retain more flexibility, but national procurement rules still apply and vary by Member State. In practice, even below-threshold procurement of AI tools should follow a documented competitive process to satisfy audit requirements and demonstrate value for money.

When writing technical specifications for an AI documentation tool, administrators should avoid specifications so narrow they effectively describe a single vendor's product, as this is prohibited under the directive. Instead, specifications should describe functional requirements (for example, real-time transcription in the relevant language, structured output compatible with the existing medical record system, EU data residency) and compliance requirements (for example, GDPR compliance, EU AI Act conformity documentation, ISO 27001 certification).

Contract terms should include:

• Clear data ownership provisions confirming that all patient data and generated notes remain the property of the municipality or the relevant health authority

• Exit provisions that allow the municipality to retrieve its data and transition to an alternative vendor without prohibitive cost or technical lock-in

• Audit rights allowing the municipality to verify compliance with data processing obligations during the contract term

The OECD has noted that most EU health systems lack dedicated reimbursement structures for AI tools, and has highlighted collective purchasing models, such as five Dutch hospitals pooling resources to evaluate AI systems, as a mechanism for equitable deployment. Municipalities considering joint procurement with neighbouring authorities or regional health bodies should assess whether this model could reduce evaluation costs and strengthen their negotiating position.

The practical questions administrators ask before piloting

Based on documented evaluations and procurement guidance, the operational and governance questions most commonly raised before a pilot is approved include:

• Who owns the output data? The structured notes generated by the tool are clinical records. Ownership and custodianship must be unambiguous in the contract.

• What happens if the tool makes an error? The clinician who reviews and approves the note retains clinical and legal responsibility. Administrators should confirm this is explicit in the vendor agreement and that the tool does not present output in a way that might reduce clinician vigilance during review.

• How is patient consent managed? Patients must be informed that an AI tool is present during their appointment. Administrators need a clear, documented process for obtaining and recording this information.

• How is staff consent managed? Staff whose voices are captured by the tool are also data subjects. Their rights under GDPR apply, and their consent or another lawful basis must be established.

• What audit trails are required? Clinical governance requires that it is possible to reconstruct what happened during an encounter and who approved the resulting note. Administrators should confirm what logs the tool maintains and for how long.

• How does the tool interact with the existing medical record system? Integration requirements vary significantly. Some tools export structured text that must be manually imported; others integrate directly via application programming interface (API). The integration model affects both workflow design and data security assessment.

A peer-reviewed study examining health technology procurement in Swedish municipalities found that structured use of evidence in procurement and evaluation decisions is inconsistent, and that existing national guidance is insufficient to support municipalities in making well-evidenced decisions. This finding underscores the importance of building internal evaluation capacity rather than relying solely on vendor-provided evidence.

How to structure a low-risk pilot in a community health programme

A well-scoped pilot reduces regulatory exposure, generates usable evidence, and creates a foundation for a defensible deployment decision. The following elements characterise a low-risk pilot design:

• Defined scope: Limit the pilot to a specific care team, programme, or site. A single community nursing team or a mental health follow-up programme is more manageable than a municipality-wide rollout.

• Defined duration: Six to twelve weeks is sufficient to generate meaningful data on documentation time, staff experience, and note quality. The Farsund Municipality pilot ran for six weeks and produced clear, quantifiable outcomes.

• Pre-agreed success criteria: Define in advance what a successful pilot looks like. Relevant metrics include documentation time per visit, staff-reported usability scores, error rates in generated notes, and patient feedback on the experience of having the tool present.

• Governance sign-offs: Before the pilot begins, obtain written sign-off from the Data Protection Officer (DPIA completed), the procurement lead (contract and data processing agreement in place), and the clinical lead (clinical governance framework agreed). Document these approvals.

• Staff training: Ensure all participating staff understand how the tool works, what their review responsibilities are, and how to report errors or concerns. The WHO/Europe report on AI in healthcare, the first comprehensive review across all 27 EU Member States, identifies workforce training and AI literacy as among the most significant factors in successful AI deployment.

• Patient communication: Prepare a clear, plain-language explanation for patients about the tool's presence and purpose. This should be available in the languages spoken by the patient population served.

• Exit plan: Define what happens to data, notes, and access rights if the pilot is discontinued or the vendor relationship ends before full deployment.

Vendor assessment: what to look for beyond the sales pitch

The following attributes should be verified independently, not accepted on the basis of marketing materials:

• ISO 27001 certification: This is the international standard for information security management. Request the current certificate and verify its scope covers the systems used to process health data.

• GDPR data processing agreement: This must be in place before any data is shared. Review it against the Article 28 requirements and ensure it reflects the actual processing activities.

• EU AI Act conformity documentation: Ask for the vendor's written risk classification assessment and any conformity documentation required under their classification tier.

• Medical device status: If the tool holds a CE mark as a medical device, request the Declaration of Conformity and verify the notified body involved.

• Data residency confirmation: Obtain written confirmation of where data is processed and stored at every stage, including sub-processors.

• Model training transparency: Ask explicitly whether patient data from your deployment will be used to train or fine-tune the model. If so, what is the legal basis, and can you opt out?

• Evidence from comparable settings: Request references or published evidence from deployments in public sector or municipal health settings in Europe. Peer-reviewed or preregistered studies carry more weight than internal case studies.

• Language capability: Confirm that the tool performs accurately in the specific language(s) used by your clinical staff, including regional dialects or clinical terminology specific to your national health system.

A crossover randomised controlled trial evaluating AI-assisted clinical coding in Sweden and Norway, conducted by the Norwegian Centre for E-Health Research, provides a useful methodological reference for rigorous evaluation study design, though it should be noted that clinical coding assessment differs from evaluating ambient documentation tools. Administrators can use the trial's methodology as a benchmark when assessing the quality of evidence vendors present for their specific use case.

One limitation in the current evidence base is worth noting: most published evaluations of AI documentation tools rely on self-reported outcomes such as perceived time savings or usability scores. Objective measurement of documentation quality, error rates, and downstream clinical outcomes remains limited. Administrators should weight vendor claims accordingly and, where possible, build objective measurement into their own pilot design.

Building the internal case: aligning procurement, legal, and clinical teams

AI documentation tools sit at the intersection of at least four regulatory frameworks, GDPR, the EU AI Act, MDR, and public procurement law, and typically require sign-off from at least three internal functions: procurement, legal/data protection, and clinical leadership. In municipal settings, these functions may not routinely work together, and each may have a different primary concern.

A practical approach to internal alignment involves:

• Starting with the Data Protection Officer. The DPIA is a prerequisite for any pilot involving special category health data. Engaging the Data Protection Officer early, before vendor selection, avoids the common situation where a preferred vendor is identified and then fails the data protection assessment.

• Framing the clinical case in operational terms. Clinical leads are more likely to engage with a proposal framed around documentation burden reduction and time recovery than one framed around technology adoption. The evidence from Farsund and the Swedish multi-site study provides concrete figures that can anchor this conversation.

• Giving procurement the regulatory context they need. Procurement teams may not be familiar with the EU AI Act or MDR. Providing a clear summary of which obligations apply, and which are the vendor's responsibility versus the municipality's, helps procurement write specifications and evaluate bids accurately.

• Documenting every decision. In a regulated procurement environment, the audit trail matters. Every decision, to proceed, to pause, to exclude a vendor, should be documented with a rationale.

Norway's national AI plan for healthcare, led by the Norwegian Directorate of Health, explicitly targets scaling AI across both municipal and specialist care settings, and includes real-world deployments such as Vestre Viken Health Trust's AI rollout serving 22 municipalities and approximately 500,000 people. This national-level commitment provides a useful reference point for municipal administrators seeking to build internal support for evaluation. It demonstrates that AI documentation tools are being taken seriously at a policy level, not treated as experimental.

What good evaluation looks like: emerging standards across Europe

Across Europe, the approach to evaluating AI documentation tools in public health settings is still maturing. There is no single agreed standard, but several frameworks and initiatives are shaping what good evaluation looks like.

The European Commission's SHAIPED project, launched in March 2025, is piloting AI model development and validation using the HealthData@EU infrastructure. This cross-border initiative is building shared infrastructure for evaluating AI in healthcare at scale, relevant for municipalities that want to align their evaluation approaches with emerging EU-level standards.

The WHO/Europe report published in April 2026, based on data collected from all 27 EU Member States between June 2024 and March 2025, found that 81 per cent of Member States are actively involving stakeholders in AI governance, and that the majority are already deploying AI tools in clinical settings. It identifies the need for structured evaluation frameworks and workforce AI literacy as priorities across the region. (Note: This is a recently published source; readers should verify the statistics and findings directly from the official WHO/Europe report.)

For municipal administrators, evaluation frameworks are available but not yet standardised. The most credible approaches share several characteristics:

• Pre-registration of evaluation protocols (as in the Swedish multi-site scribe study)

• Use of validated usability instruments alongside time-based metrics

• Inclusion of patient experience data, not only staff experience

• Independent or third-party review of vendor-provided evidence

• Transparent reporting of negative findings or limitations alongside positive outcomes

The open-source Berta documentation tool, deployed across 105 urban and rural facilities by 198 emergency physicians between November 2024 and July 2025, represents one model for transparent evaluation. Its development and deployment methodology is publicly documented, allowing external scrutiny. While open-source tools introduce their own governance considerations, the transparency of their evaluation approach offers a useful reference point.

Administrators building their own evaluation frameworks should also monitor guidance from their national health authorities and data protection supervisory authorities, both of which are increasingly publishing AI-specific guidance. The regulatory environment is active: what is current best practice in mid-2026 may be superseded by formal guidance within the next twelve to eighteen months. Evaluation frameworks should be designed to accommodate that evolution.

Frequently asked questions

▶ What do AI-assisted documentation tools actually do during a community health visit?

An AI-assisted documentation tool listens to a patient visit, transcribes the encounter, and generates a draft clinical note. The clinician reviews and approves that note before it enters the medical record system. The tool doesn't diagnose, prescribe, or generate clinical recommendations. Its function is administrative: converting speech into structured text for clinician review.

▶ What evidence exists for time savings in municipal public health settings?

A six-week pilot in Farsund Municipality, Norway, involving twenty employees across three care teams, found that total daily documentation time fell from approximately three hours to ten to fifteen minutes. A separate large-scale observational study across Capio/Ramsay Santé facilities in Sweden, evaluating an AI medical assistant across 375,000 clinical notes, found consistent reductions in self-reported documentation time across multiple care levels. That study was preregistered and adhered to SQUIRE reporting guidelines. Most published evaluations do rely on self-reported outcomes, so administrators should build objective measurement into their own pilot design where possible.

▶ Does the EU AI Act classify documentation tools as high-risk?

The EU Artificial Intelligence Act, which came into force in August 2024, classifies AI systems used for diagnosis, treatment decisions, or clinical decision support as high-risk. A documentation tool whose sole function is transcribing and structuring clinical encounters without generating clinical recommendations occupies a different position. Administrators should ask vendors for a written risk classification rationale and verify that the tool doesn't include any decision-support features that would shift its classification into the high-risk category.

▶ What GDPR obligations apply before a pilot begins?

Health data is special category data under Article 9 of the General Data Protection Regulation. Before any pilot, municipalities must conduct a Data Protection Impact Assessment, which is mandatory under Article 35 when processing special category health data using new technology. A signed data processing agreement with the vendor, required under Article 28, must also be in place before any data is shared. Administrators should establish the lawful basis for processing and document that determination before the pilot starts.

▶ How do municipalities confirm that patient data stays within the EU?

Administrators should obtain written confirmation from the vendor on where audio data is processed at the point of transcription, where structured notes are stored and for how long, whether any sub-processors are involved and where they're located, and whether any data is transferred outside the EU or European Economic Area at any stage, including for model training or quality assurance. Vendors using infrastructure outside the EEA should specify the legal transfer mechanism in use, such as Standard Contractual Clauses.

▶ When does the EU Medical Device Regulation apply to an AI documentation tool?

The EU Medical Device Regulation applies to software intended for a medical purpose, including diagnosis, monitoring, or treatment. A tool whose sole function is transcribing and structuring clinical encounters, without generating any output that influences clinical decisions, is generally not considered a medical device. If a tool includes features such as flagging clinical abnormalities or suggesting diagnoses, those features may bring it within scope. Administrators should ask vendors for a written Medical Device Regulation classification rationale and verify whether the tool holds a CE mark as a medical device.

▶ What procurement rules apply when a municipality buys an AI documentation tool?

AI documentation tools procured by European municipal public health bodies are subject to the EU public procurement framework under Directive 2014/24/EU. For sub-central public bodies, the current services contract threshold is €215,000 net of VAT, though this figure is revised periodically and should be verified against the most recent Commission Delegated Regulation. Contracts above this threshold require a formal tender procedure. Below threshold, national procurement rules still apply. Technical specifications should describe functional and compliance requirements rather than a single vendor's product, which is prohibited under the directive.

▶ Who is responsible if an AI-generated clinical note contains an error?

The clinician who reviews and approves the note retains clinical and legal responsibility. Administrators should confirm this is explicit in the vendor agreement and that the tool doesn't present output in a way that might reduce clinician vigilance during review. The audit trail, including logs of who approved each note and when, should be confirmed with the vendor before the pilot begins.

▶ How should a municipality structure a low-risk pilot?

A well-scoped pilot limits scope to a specific care team or site, runs for six to twelve weeks, and defines success criteria in advance. Relevant metrics include documentation time per visit, staff-reported usability scores, error rates in generated notes, and patient feedback. Before the pilot begins, written sign-off is needed from the Data Protection Officer, the procurement lead, and the clinical lead. Staff training, a clear patient communication process, and a documented exit plan should all be in place before any data is processed.

▶ What should administrators verify independently when assessing a vendor?

Administrators should verify ISO 27001 certification, confirming its scope covers the systems used to process health data. They should review the General Data Protection Regulation data processing agreement against Article 28 requirements, request EU AI Act conformity documentation, and confirm medical device status if a CE mark is claimed. Written confirmation of data residency at every stage of processing, including sub-processors, is essential. Administrators should also ask explicitly whether patient data will be used to train or fine-tune the model, and request evidence from deployments in comparable European public sector settings.